

(A)
SN38
HER2low BC
CRC
Proliferation at 120h (%)
Drug concentration [M]
(B)
Topotecan
NSCLC
Topotecan
Cpd of formula (I)
Topotecan + Cpd of formula (I) 300nM

Figure 1



MDA-MB-231
Synergy Score
Cpd of formula (I) (uM)
SG (uM)
MDA-MB-231-Luc-D3H2LN cell growth (% inhibition)
Cpd of Formula (I) (uM)
0
0.5
1
2
4
8
SG (uM)
HCC-38
Synergy Score
Cpd of formula (I) (uM)
SG (uM)
HCC38 cell growth (% inhibition)
Cpd of Formula (I) (uM)
0
0.5
1
2
4
8
SG (uM)

Figure 2




Figure 2 (cont.)



D54
Synergy Score
Cpd of formula (I) (uM)
SG (uM)
D54-Luc cell growth (% inhibition)
Cpd of Formula (I) (uM)
0
0.62
1.85
5.56
16.7
50
SG (uM)
U87MG
Synergy Score
Cpd of formula (I) (uM)
SG (uM)
U-87 MG-luc cell growth (% inhibition)
SG (uM)

Figure 3



Colo205
HCT-116
SW480
Synergy Score
Cpd of formula (I) (uM)
SG (uM)
COLO 205-Luc #2 cell growth (% inhibition)
HCT 116-Luc cell growth (% inhibition)
SW480 cell growth (% inhibition)
Cpd of Formula (I) (uM)
0
0.62
1.85
5.56
16.7
50

Figure 4



A
MDA-MB-468 (TNBC)
Vehicle
Cpd of formula (I) 30mg/kg
SG 8mg/kg
SG 8mg/kg + Cpd of formula (I) 30mg/kg
Mean Tumor Volume +/- SE (mm³)
Days post transplant
B
Vehicle
Cpd of formula (I) 30mg/kg
SG 12.5mg/kg
SG 12.5mg/kg + Cpd of formula (I) 30mg/kg
Mean Tumor Volume +/- SE (mm³)
Days Post Tumor Implant

Figure 5



A
Mean Tumor Volume +/- SE (mm³)
Days Post Tumor Implant
B
Mean BLI Signal (photons/sec)
Days Post Tumor Implant
Vehicle
Cpd of formula (I) 30mg/kg QD
SG 12.5mg/kg QW
Cpd of formula (I) 30mg/kg + SG 12.5mg/kg
C
% Survival
Days Post Transplant

Figure 6



Breast PDX
Tumor volume (mm3)
1500
1000
500
400
300
200
100
0
0
7
14
21
28
35
Days post randomization
Vehicle
Cpd of formula (I) 30mg/kg QD
Dato-Dxd 6mg/kg QWx2
Dato-Dxd + Cpd of formula (I)

Figure 7



CRC PDX
2500
2000
1500
1000
500
0
Tumor volume (mm3)
0
7
14
21
28
Days after randomization
Vehicle
Cpd formula (I) 30mg/kg QD
Dato-Dxd 6mg/kg QWx2
Dato-Dxd + Cpd of formula (I)

Figure 8



CRC PDX
Tumor volume (mm3)
2500
2000
1500
1000
500
0
0
7
14
21
28
Days post randomization
Vehicle
Cpd of formula (I) 30mg/kg QD
Sacituzumab govitecan 12.5mg/kg QWx4
Sacituzumab govitecan + Cpd of formula (I)

Figure 9



NSCLC PDX
Tumor volume (mm3)
2500
2000
1500
1000
500
0
0
7
14
21
28
35
Days post randomization
Vehicle Control
Sacituzumab govitecan 10mg/kg QWx4
Cpd of formula (I) 30mg/kg QD
Cpd of formula (I) + Sacituzumab govitecan

Figure 10



Ovarian PDX
1500
1000
500
0
Tumor volume (mm3)
0
20
40
60
Days post randomization
Vehicle
Cpd of formula (I) 30mg/kg QD
Sacituzumab govitecan 10mg/kg QWx2
Cpd of formula (I) + Sacituzumab govitecan

Figure 11